Clinical Trial Update: A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA) [Phase 2]

View source ↗

Summary

A Phase 2 safety and efficacy study of intra-articular canakinumab and LNA043 for knee osteoarthritis was terminated, with results posted in 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Knee Osteoarthritis

Drugs mentioned

• ILARIS (canakinumab)
• LNA043

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Knee Osteoarthritis | Phase 2 | Status: TERMINATED | Results posted: 2025-07-30